Use of Antiviral Agents and other Therapies for COVID-19

被引：2
|
作者：
Blaskovich, Mark A. T. [1 ,2 ]
Verderosa, Anthony D. [1 ]
机构：
[1] Univ Queensland, Inst Mol Biosci, Ctr Superbug Solut, St Lucia, Qld, Australia
[2] Univ Queensland, Inst Mol Biosci, Ctr Superbug Solut, 306 Carmody Rd Bldg 80, St Lucia, Qld 4072, Australia
来源：
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 44卷 / 01期
关键词：
COVID-19; SARS-CoV-2; antiviral; protease inhibitor; polymerase inhibitor; EPIDEMIC PREPAREDNESS; PROTEASE INHIBITOR; IVERMECTIN; HYDROXYCHLOROQUINE; CHLOROQUINE; ENTRY;
D O I：
10.1055/s-0042-1758837
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
The coronavirus disease 2019 (COVID-19) pandemic led to a remarkably rapid development of a range of effective prophylactic vaccines, including new technologies that had not previously been approved for human use. In contrast, the development of new small molecule antiviral therapeutics has taken years to produce the first approved drugs specifically targeting severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), with the intervening years filled with attempts to repurpose existing drugs and the development of biological therapeutics. This review will discuss the reasons behind this variation in timescale and provide a survey of the many new treatments that are progressing through the clinical pipeline.
引用
收藏
页码：118 / 129
页数：12
相关论文
共 50 条
  • [31] Transcatheter Therapies For COVID-19
    Kipshidze, Nicholas
    White, Christopher
    Kipshidze, Nodar
    Reddy, Vivek
    Dangas, George
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (17) : B94 - B94
  • [32] Alternative therapies for Covid-19
    Sundararajan, G.
    Isaac, Prince J.
    Andal, V
    Lakshmipathy, R.
    MATERIALS TODAY-PROCEEDINGS, 2022, 55 : 327 - 329
  • [33] Immunomodulatory therapies for COVID-19
    Mathur, Poonam
    Kottilil, Shyamasundaran
    FRONTIERS IN MEDICINE, 2022, 9
  • [34] Effect of use of oral antiviral agents on reducing critical illness and mortality for patients with moderate to severe COVID-19
    Jin, Zhao Jun
    Deng, Min
    Chen, Yi Min
    Tong, Ming Kai
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [35] Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19)
    Yip, Terry Cheuk-Fung
    Lui, Grace Chung-Yan
    Lai, Mandy Sze-Man
    Wong, Vincent Wai-Sun
    Tse, Yee-Kit
    Ma, Bosco Hon-Ming
    Hui, Elsie
    Leung, Maria K. W.
    Chan, Henry Lik-Yuen
    Hui, David Shu-Cheong
    Wong, Grace Lai-Hung
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E26 - E33
  • [36] The clinical outcomes and effectiveness of antiviral agents among underweight patients with COVID-19
    Wu, Jheng-Yan
    Liu, Mei-Yuan
    Lee, Mei-Chuan
    Hung, Kuo-Chuan
    Hsu, Wan-Hsuan
    Tsai, Ya-Wen
    Liu, Ting-Hui
    Huang, Po-Yu
    Chuang, Min-Hsiang
    Tseng, Shu-Ching
    Lu, Chih-Ying
    Lai, Chih-Cheng
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (05) : 343 - 352
  • [37] Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19
    Apaydin, Cagla Begum
    Cinar, Gozde
    Cihan-Ustundag, Gokce
    CURRENT DRUG TARGETS, 2021, 22 (17) : 1986 - 2005
  • [38] Topical Oral and Intranasal Antiviral Agents for Coronavirus Disease 2019 (COVID-19)
    Hsue, Victor B.
    Itamura, Kyohei
    Wu, Arthur W.
    Illing, Elisa A.
    Sokoloski, Kevin J.
    Weaver, Bree A.
    Anthony, Benjamin P.
    Hughes, Nathan
    Ting, Jonathan Y.
    Higgins, Thomas S.
    IDENTIFCATION OF BIOMARKERS, NEW TREATMENTS, AND VACCINES FOR COVID-19, 2021, 1327 : 169 - 189
  • [39] Emerging Oral Antiviral Therapies for COVID-19, Early Evidence for the Clinical Nurse Specialist
    O'Malley, Patricia
    CLINICAL NURSE SPECIALIST, 2022, 36 (02) : 81 - 83
  • [40] A prospect on the use of antiviral drugs to control local outbreaks of COVID-19
    Andrea Torneri
    Pieter Libin
    Joris Vanderlocht
    Anne-Mieke Vandamme
    Johan Neyts
    Niel Hens
    BMC Medicine, 18
12345